GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...

Teva Pharmaceutical Industries Ltd. ADR-3.78% $21.4B ...

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...